1. Home
  2. OGEN vs NAOV Comparison

OGEN vs NAOV Comparison

Compare OGEN & NAOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OGEN
  • NAOV
  • Stock Information
  • Founded
  • OGEN 1996
  • NAOV 2003
  • Country
  • OGEN United States
  • NAOV United States
  • Employees
  • OGEN N/A
  • NAOV N/A
  • Industry
  • OGEN Biotechnology: Pharmaceutical Preparations
  • NAOV Industrial Specialties
  • Sector
  • OGEN Health Care
  • NAOV Health Care
  • Exchange
  • OGEN Nasdaq
  • NAOV Nasdaq
  • Market Cap
  • OGEN 4.6M
  • NAOV 5.4M
  • IPO Year
  • OGEN N/A
  • NAOV N/A
  • Fundamental
  • Price
  • OGEN $0.20
  • NAOV $5.15
  • Analyst Decision
  • OGEN
  • NAOV
  • Analyst Count
  • OGEN 0
  • NAOV 0
  • Target Price
  • OGEN N/A
  • NAOV N/A
  • AVG Volume (30 Days)
  • OGEN 376.3K
  • NAOV 4.9M
  • Earning Date
  • OGEN 05-14-2025
  • NAOV 05-14-2025
  • Dividend Yield
  • OGEN N/A
  • NAOV N/A
  • EPS Growth
  • OGEN N/A
  • NAOV N/A
  • EPS
  • OGEN N/A
  • NAOV N/A
  • Revenue
  • OGEN N/A
  • NAOV $2,558,000.00
  • Revenue This Year
  • OGEN N/A
  • NAOV N/A
  • Revenue Next Year
  • OGEN N/A
  • NAOV N/A
  • P/E Ratio
  • OGEN N/A
  • NAOV N/A
  • Revenue Growth
  • OGEN N/A
  • NAOV 12.05
  • 52 Week Low
  • OGEN $0.16
  • NAOV $1.92
  • 52 Week High
  • OGEN $3.43
  • NAOV $16.25
  • Technical
  • Relative Strength Index (RSI)
  • OGEN 43.74
  • NAOV 48.45
  • Support Level
  • OGEN $0.16
  • NAOV $5.86
  • Resistance Level
  • OGEN $0.21
  • NAOV $6.24
  • Average True Range (ATR)
  • OGEN 0.01
  • NAOV 1.58
  • MACD
  • OGEN 0.00
  • NAOV -0.10
  • Stochastic Oscillator
  • OGEN 74.00
  • NAOV 20.77

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

About NAOV NanoVibronix Inc.

NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements.

Share on Social Networks: